Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer
Thomas Powles • 30 May 2015
Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Thomas Powles • 8 Feb 2018
INTACT: safety results of CRT with and without atezolizumab in MIBC
Parminder Singh • 16 Feb 2021